Prognostic factors for the selection of patients eligible for second-line chemotherapy in advanced biliary tract cancer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The efficacy of second-line chemotherapy (CT2) after the failure of first-line chemotherapy (CT1) for advanced biliary tract cancer (BTC) has not been established. We investigated the favorable prognostic factors for CT2 to determine which patients could be expected to benefit from CT2. Methods: From a total of 168 patients who were treated with chemotherapy at our institution between January 2003 and December 2012, we retrospectively reviewed 50 patients who received CT2. Patients were treated with various chemotherapeutic combinations as CT1 and CT2. Results: The median overall survival (OS) of patients who received and CT2 was 10.2 and 5.5 months, respectively. Good performance status (PS), a serum albumin level >3.5 g/dl and metastasis to only 1 organ were independent prognostic factors that affected the OS of the patients who received CT2. Patients who had only 1 metastastic organ, a good PS and a serum albumin level >3.5 g/dl at the beginning of CT2 demonstrated prolonged survival compared to patients who did not exhibit these 3 factors (9.5 vs. 4.3 months, p < 0.005). Conclusions: CT2 should be considered for patients with advanced BTC, especially for those who have only 1 metastatic organ and remain in generally good medical condition after the failure of CT1.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalChemotherapy
Volume60
Issue number2
DOIs
Publication statusPublished - 2014 Mar 24

Fingerprint

Biliary Tract Neoplasms
Patient Selection
Drug Therapy
Serum Albumin
Survival
Neoplasm Metastasis

Keywords

  • Biliary tract cancer
  • Prognostic factors
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this

@article{57f19de999db4373a8ddd2cc150c65d4,
title = "Prognostic factors for the selection of patients eligible for second-line chemotherapy in advanced biliary tract cancer",
abstract = "Background: The efficacy of second-line chemotherapy (CT2) after the failure of first-line chemotherapy (CT1) for advanced biliary tract cancer (BTC) has not been established. We investigated the favorable prognostic factors for CT2 to determine which patients could be expected to benefit from CT2. Methods: From a total of 168 patients who were treated with chemotherapy at our institution between January 2003 and December 2012, we retrospectively reviewed 50 patients who received CT2. Patients were treated with various chemotherapeutic combinations as CT1 and CT2. Results: The median overall survival (OS) of patients who received and CT2 was 10.2 and 5.5 months, respectively. Good performance status (PS), a serum albumin level >3.5 g/dl and metastasis to only 1 organ were independent prognostic factors that affected the OS of the patients who received CT2. Patients who had only 1 metastastic organ, a good PS and a serum albumin level >3.5 g/dl at the beginning of CT2 demonstrated prolonged survival compared to patients who did not exhibit these 3 factors (9.5 vs. 4.3 months, p < 0.005). Conclusions: CT2 should be considered for patients with advanced BTC, especially for those who have only 1 metastatic organ and remain in generally good medical condition after the failure of CT1.",
keywords = "Biliary tract cancer, Prognostic factors, Second-line chemotherapy",
author = "Kang, {Eun Joo} and Choi, {Yoon Ji} and Kim, {Jung Sun} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Kim, {Hong Jun} and Kang, {Ka Won} and Yu, {Eun Sang} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk}",
year = "2014",
month = "3",
day = "24",
doi = "10.1159/000370193",
language = "English",
volume = "60",
pages = "91--98",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Prognostic factors for the selection of patients eligible for second-line chemotherapy in advanced biliary tract cancer

AU - Kang, Eun Joo

AU - Choi, Yoon Ji

AU - Kim, Jung Sun

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Kim, Hong Jun

AU - Kang, Ka Won

AU - Yu, Eun Sang

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

PY - 2014/3/24

Y1 - 2014/3/24

N2 - Background: The efficacy of second-line chemotherapy (CT2) after the failure of first-line chemotherapy (CT1) for advanced biliary tract cancer (BTC) has not been established. We investigated the favorable prognostic factors for CT2 to determine which patients could be expected to benefit from CT2. Methods: From a total of 168 patients who were treated with chemotherapy at our institution between January 2003 and December 2012, we retrospectively reviewed 50 patients who received CT2. Patients were treated with various chemotherapeutic combinations as CT1 and CT2. Results: The median overall survival (OS) of patients who received and CT2 was 10.2 and 5.5 months, respectively. Good performance status (PS), a serum albumin level >3.5 g/dl and metastasis to only 1 organ were independent prognostic factors that affected the OS of the patients who received CT2. Patients who had only 1 metastastic organ, a good PS and a serum albumin level >3.5 g/dl at the beginning of CT2 demonstrated prolonged survival compared to patients who did not exhibit these 3 factors (9.5 vs. 4.3 months, p < 0.005). Conclusions: CT2 should be considered for patients with advanced BTC, especially for those who have only 1 metastatic organ and remain in generally good medical condition after the failure of CT1.

AB - Background: The efficacy of second-line chemotherapy (CT2) after the failure of first-line chemotherapy (CT1) for advanced biliary tract cancer (BTC) has not been established. We investigated the favorable prognostic factors for CT2 to determine which patients could be expected to benefit from CT2. Methods: From a total of 168 patients who were treated with chemotherapy at our institution between January 2003 and December 2012, we retrospectively reviewed 50 patients who received CT2. Patients were treated with various chemotherapeutic combinations as CT1 and CT2. Results: The median overall survival (OS) of patients who received and CT2 was 10.2 and 5.5 months, respectively. Good performance status (PS), a serum albumin level >3.5 g/dl and metastasis to only 1 organ were independent prognostic factors that affected the OS of the patients who received CT2. Patients who had only 1 metastastic organ, a good PS and a serum albumin level >3.5 g/dl at the beginning of CT2 demonstrated prolonged survival compared to patients who did not exhibit these 3 factors (9.5 vs. 4.3 months, p < 0.005). Conclusions: CT2 should be considered for patients with advanced BTC, especially for those who have only 1 metastatic organ and remain in generally good medical condition after the failure of CT1.

KW - Biliary tract cancer

KW - Prognostic factors

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84925446598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925446598&partnerID=8YFLogxK

U2 - 10.1159/000370193

DO - 10.1159/000370193

M3 - Article

VL - 60

SP - 91

EP - 98

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 2

ER -